PO-79 | Survey on adherence and tolerability of atogepant used as migraine preventive treatment
D.A. Montisano,1 G. Vaghi,2,3 A. Paris,1 R. De Icco,2,3 B. Agostini,2,3 M. Giraudo,2,3 A. Solfrizzi,2,3 C. Tassorelli,2,3 G. Sances,3 L. Grazzi | 1Fondazione IRCCS C.Besta Istituto Neurologico, SSD Headache Center, Milan, Italy; 2University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy; 3IRCCS Mondino Foundation, Headache Science & Neurorehabilitation Unit, Pavia, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Atogepant is a novel anti-calcitonin gene-related peptide treatment (CGRP) used in migraine prevention. Our primary aim was to assess its therapeutic adherence, tolerability of the drug, as well as perceived effectiveness when used during a migraine attack.
Methods: We conducted a survey involving 51 migraine individuals undergoing atogepant treatment at the Headache Centers of Carlo Besta Neurological Institute in Milan and Mondino Foundation in Pavia. The survey was made on "Microsoft Form" institutional doodle. We investigated therapeutic adherence, treatment tolerability, individuals’ satisfaction, as well as atogepant efficacy despite some missed pills missed, and acute effectiveness during pain.
Results: Participants had a mean age of 42y (±8.4), they received treatment for a median of 24 weeks of them 42 out of 51 take atogepant in the morning. Of the total sample, 59% of individuals missed few pills during the follow-up period. Among them, approximately 70% noticed no change in the drug’s effectiveness, suggesting a degree of resilience to occasional non-adherence. Almost all respondents (72.5%) reported a high level of satisfaction with the treatment, describing a “significant improvement” in managing migraine attacks. Twenty-one participants took atogepant during an acute attack, determining pain freedom within 2hours from intake in 16/21. Adverse effects were reported by 48% of participants, mainly nausea and mild average weight loss (of approximately 2 kg). Only two individuals dropped out due to adverse event (e.g. nausea) after 6 months of treatment.
Conclusion: Overall, atogepant proved to be a well-tolerated treatment, with high adherence in clinical practice. Clinical efficacy was maintained despite some missed pills. Mild adverse events were declared by half of participants, mainly nausea and slight weight loss.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.